Hematologic Oncology | Specialty

Updated Data Confirm Long-Term Benefit With Tafasitamab/Lenalidomide in Relapsed/Refractory DLBCL

July 24th 2020

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Selinexor Triplet Shows Strong Clinical Activity in Relapsed/Refractory Myeloma

July 24th 2020

A triplet regimen comprised of selinexor, daratumumab, and dexamethasone proved to be highly active, inducing deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Shammo Previews the Potential of Pevonedistat Combo in High-Risk MDS

July 23rd 2020

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Genetic Testing Could Lead to Improved Treatment Decisions, Predicted Outcomes in MPNs, MDS

July 23rd 2020

Mutually exclusive gene combinations were observed between specific subtypes of patients with myelodysplastic syndromes and myeloproliferative neoplasms and most other types of MDS/MPNs that have an impact on patient outcomes.

Ruxolitinib Improves ORR in Steroid-Refractory, Dependent Chronic GVHD

July 23rd 2020

Ruxolitinib was found to demonstrate a superior objective response rate at 24 weeks compared with best available therapy in patients with steroid-refractory or steroid-dependent chronic graft-versus-host-disease, meeting the primary end point of the phase 3 REACH3 trial.

Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL

July 23rd 2020

Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.

Dr. Mesa on Rechallenging With JAK Inhibitor Therapy in MPNs

July 23rd 2020

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

CCC-19 Registry Data Show Increased COVID-19–Associated Mortality in Patients With Cancer

July 22nd 2020

The mortality rate with COVID-19 appears to be higher in patients with cancer—especially those with lung cancer—compared with the general population, and several factors associated with mortality are beginning to emerge.

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies

July 22nd 2020

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

FDA Sets Review Date for Remestemcel-L for Steroid-Refractory Pediatric Acute GVHD

July 21st 2020

The FDA’s Oncologic Drugs Advisory Committee has scheduled a date to review data supporting the biologics license application for remestemcel-L as a treatment for children with steroid-refractory acute graft versus host disease.

Dr. Komrokji on the Current Treatment Landscape in MDS

July 21st 2020

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

July 21st 2020

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

FDA Approval Sought for Selinexor in Myeloma After 1 Prior Line of Therapy

July 20th 2020

The FDA has accepted a supplemental new drug application seeking approval for selinexor for the treatment of patients with multiple myeloma following at least 1 previous line of therapy.

Progress in the Treatment of AML

July 20th 2020

Implications for Treating AML With CC-486

July 20th 2020

CC-486 Maintenance Therapy in AML

July 20th 2020

Gemtuzumab for AML

July 20th 2020

CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020